Table 1.
Comparison of characteristics and biomarkers by group. Group comparison p values were obtained using one-way ANOVA (age), chi squared tests (sex), or Kruskal-Wallis tests (remainder). Post-hoc comparisons were made using Dunn’s test; the presented p values are Bonferroni corrected
| CAA (n = 10) | AD (n = 20) | CS (n = 10) | Group comparison, p | Post-hoc comparisons; p | |||
| CAA/AD | CAA/CS | AD/CS | |||||
| Age, y, mean (SD) | 68.6 (3.0) | 62.5 (4.1) | 62.2 (5.4) | 0.001 | – | – | – |
| Sex, female, n (%) | 2 (20%) | 11 (55%) | 5 (50%) | 0.18 | – | – | – |
| MMSE, median (IQR) | 29 (28 to 30) | 24 (19.5 to 26) | 29 (29 to 30) | <0.001 | – | – | – |
| Biomarkers | |||||||
| Aβ38, pg/ml, median (IQR) | 1490 (1350 to 2450) | 2740 (2360 to 3270) | 2840 (2150 to 3280) | 0.002 | 0.002 | 0.004 | 1.00 |
| Aβ40, pg/ml, median (IQR) | 3150 (2940 to 4140) | 6470 (5760 to 7330) | 6890 (5080 to 7600) | <0.001 | <0.001 | <0.001 | 1.00 |
| Aβ42, pg/ml, median (IQR) | 115 (91.4 to 134) | 323 (264 to 376) | 520 (280 to 814) | <0.001 | <0.001 | <0.001 | 0.37 |
| sAβPPα, pg/ml, median (IQR) | 88.6 (67.9 to 100) | 115 (99.0 to 137) | 117 (105 to 136) | 0.008 | 0.007 | 0.013 | 1.00 |
| sAβPPβ, pg/ml, median (IQR) | 85.8 (66.3 to 104) | 118 (102 to 142) | 124 (97.5 to 144) | 0.009 | 0.006 | 0.018 | 1.00 |
| t-tau, pg/ml, median (IQR) | 316 (247 to 440) | 657 (497 to 869) | 250 (206 to 266) | <0.001 | <0.001 | 0.35 | <0.001 |
| p-tau, pg/ml, median (IQR) | 62.1 (45.8 to 72.1) | 92.8 (73.6 to 112) | 49.5 (42.0 to 52.4) | <0.001 | 0.014 | 0.26 | <0.001 |
| NFL, pg/ml, median (IQR) | 2780 (2390 to 8380) | 2370 (1920 to 2730) | 1470 (1150 to 1630) | <0.001 | 0.15 | <0.001 | 0.005 |
| sTREM2, pg/ml, median (IQR) | 7040 (6240 to 9230) | 6580 (5640 to 8120) | 7960 (6130 to 9790) | 0.52 | – | – | – |
| Neurogranin, pg/ml, median (IQR) | 432 (349 to 491) | 565(454 to 702) | 409 (309 to 431) | 0.012 | 0.076 | 0.72 | 0.008 |